Recombinant EPH Receptor A2 antibody (AA 25-534)

Catalog No. ABIN7452579

This anti-EPH Receptor A2 antibody is a Rabbit Monoclonal antibody detecting EPH Receptor A2 in WB and IP. Suitable for Human.

Quick Overview for Recombinant EPH Receptor A2 antibody (AA 25-534) (ABIN7452579)

Target: EPH Receptor A2 (EPHA2)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This EPH Receptor A2 antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP)

Clone: BLR136H

Product Details anti-EPH Receptor A2 Antibody

Binding Specificity: AA 25-534

Purpose: Rabbit anti-EphA2 Recombinant Monoclonal Antibody [BLR136H]

Immunogen: residues 25-534 (ECD)

Isotype: IgG

Application Details

Application Notes:

IP: 20 μL/1 mg lysate

WB: 01:01,00

Restrictions: For Research Use only

Handling

Concentration: 40 μg/mL

Buffer: Borate Buffered Saline (BBS) pH 8.2 with 0.1 % BSA and 0.09 % Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Expiry Date: 12 months

Target Details for EPH Receptor A2

Target: EPH Receptor A2 (EPHA2)

Alternative Name: EphA2

Background: Background: Ephrin type-A receptor 2 (EphA2) is a member of the Eph family of tyrosine kinase receptors. Eph receptors have been shown to play a critical role in the development of the nervous system, where they regulate patterning during neural development. The ligands for Eph receptors are ephrins. Ephrin receptors and ligands have been found to be frequently overexpressed in a wide variety of cancers. Contrary to the usual finding that the oncogenic properties of tyrosine kinase receptors are promoted by the autophosphorylation of the receptor, it is the dephosphorylation of EphA2 that is associated with its oncogenic activity. The major study of EphA2 has been in relation to its contribution to malignancy and the possibility of targeting it in cancer therapy.

Gene ID: 1969

NCBI Accession: NP_004422

UniProt: P29317

Pathways: RTK Signaling